(Q37152144)

18 August 2017

title

Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department (English)

1 reference

multicenter clinical trial

18 August 2017

main subject

0 references

0 references

6

Carlos A Camargo

1 reference

18 August 2017

2

Sunday Clark

1 reference

18 August 2017

1

Aleena Banerji

1 reference

18 August 2017

Michelle Blanda

3

1 reference

18 August 2017

Frank LoVecchio

series ordinal

4

1 reference

18 August 2017

Brian Snyder

series ordinal

5

1 reference

18 August 2017

language of work or name

1 reference

1 April 2008

1 reference

Annals of Allergy, Asthma & Immunology

18 August 2017

published in

1 reference

18 August 2017

volume

100

1 reference

18 August 2017

issue

4

1 reference

18 August 2017

page(s)

327-332

1 reference

Airway compromise due to angiotensin-converting enzyme inhibitor-induced angioedema: clinical experience at a large community teaching hospital

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

Drug-induced angioedema without urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

Prescribing pattern of antihypertensive drugs in primary care units in Turkey: results from the TURKSAHA study.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

ACE inhibitor-induced angioedema. Incidence, prevention and management

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

Angioedema in heart failure: occurrence with ACE inhibitors and safety of angiotensin receptor blocker therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

Angioedema: the role of ACE inhibitors and factors associated with poor clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

Angioedema: 5 years' experience, with a review of the disorder's presentation and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

Angioedema in the emergency department: the impact of angiotensin-converting enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

Epidemiological study of angioedema and ACE inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

A profile of US emergency departments in 2001.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

Angiotensin-converting enzyme inhibitor-associated angioedema

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

Increased sensitivity to bradykinin among African Americans

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

Interactive Effect of Ethnicity and ACE Insertion/Deletion Polymorphism on Vascular Reactivity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

Ethnicity affects vasodilation, but not endothelial tissue plasminogen activator release, in response to bradykinin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

Fatal angioedema associated with lisinopril

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

Angiotensin-converting enzyme inhibitor-induced angioedema: late onset, irregular course, and potential role of triggers

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

Studies of the mechanism of angiotensin-converting enzyme (ACE) inhibitor-associated angioedema: the effect of an ACE inhibitor on cutaneous responses to bradykinin, codeine, and histamine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

Angiotensin-converting enzyme inhibitor-related angioedema: how to deal with it.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

C1-inhibitor deficiencies (hereditary angioedema): where are we with therapies?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960594-7

7 January 2021

10.1016/S1081-1206(10)60594-7

Identifiers

DOI

1 reference

18 August 2017

1 reference